A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Pamiparib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 11 Oct 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 03 Apr 2019 Status changed from not yet recruiting to recruiting.
- 25 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.